BioCentury | Apr 21, 2020
Product Development

Trio of tactics to target COVID-19 hyperinflammation

Three companies announced COVID-19 programs Monday aimed at blocking the excessive inflammatory response seen in severe cases. Alexion unveiled a global program for its C5 inhibitor Ultomiris, while 4D pharma moved its live biotherapeutic therapy...
BC Week In Review | Aug 17, 2017
Clinical News

Cyclacel reports Phase I data for CDK2/9 inhibitor in solid tumors

Cyclacel Pharmaceuticals Inc. (NASDAQ:CYCC) reported data from 24 heavily treated patients with advanced solid tumors in the dose-escalation part 1 of a Phase I trial showing that 8-288 mg/m 2 /day doses of CYC065 given...
BC Week In Review | Apr 13, 2017
Clinical News

CYC065: Preclinical data

In vitro , CYC065 inhibited growth, triggered apoptosis and induced anaphase catastrophe in murine and human lung cancer cells with known high metastatic potential. CYC065 also inhibited migration and invasion of lung cancer cells. Data were...
BC Extra | Feb 23, 2017
Clinical News

Cyclacel's sapacitabine fails in Phase III AML trial

Cyclacel Pharmaceuticals Inc. (NASDAQ:CYCC) lost $1.36 (25%) to $4.05 on Thursday after its sapacitabine ( CYC682 ) missed the primary endpoint in the pivotal Phase III SEAMLESS trial to treat newly diagnosed acute myelogenous leukemia in elderly...
BC Week In Review | Nov 16, 2015
Clinical News

CYC065: Phase I started

Cyclacel began an open-label, dose-escalation, U.S. Phase I trial to evaluate oral CYC065 every 3 weeks in about 35 patients. Cyclacel Pharmaceuticals Inc. (NASDAQ:CYCC), Berkeley Heights, N.J.   Product: CYC065   Business: Cancer   Molecular...
BioCentury | Mar 18, 2013

U.K. cash catalyst

U.K. cash catalyst A pair of non-British companies tapped into U.K. government largesse last week when they received awards from the U.K. Technology Strategy Board's Biomedical Catalyst fund. All told, 43 companies and eight universities...
BC Week In Review | Nov 12, 2012
Company News

Medical Research Council pharmaceuticals news

The U.K.'s three-year, £180 million ($285.8 million) Biomedical Catalyst fund awarded £39 million ($62.4 million) across 10 universities and 22 small and medium sized enterprises (SMEs) for early stage life science research. Companies receiving funding...
BC Innovations | Apr 12, 2012
Cover Story

Targeting CDK in triple-negative breast cancer

A team at the University of California, San Francisco has found a dysregulated MYC pathway that underlies the majority of triple-negative breast cancers-a form of the disease with limited treatment options. 1 The researchers also...
BC Innovations | Mar 10, 2011
Targets & Mechanisms

De-amping the HER2 environment

A team from the University of Pennsylvania School of Medicine and another from the Massachusetts General Hospital Cancer Center and Cyclacel Pharmaceuticals Inc. have independently identified strategies to improve clinical outcomes for patients with HER2-positive...
BC Week In Review | May 3, 2010
Clinical News

Cyclacel preclinical data

CYC065 induced apoptosis in CLL cell lines with about 30-fold greater potency than selicicib in vitro. CYC065 is a second-generation inhibitor of cyclin dependent kinases 2E, 2A, 7 and 9. Data were presented at the...
Items per page:
1 - 10 of 12